New York Times discusses drug patent challenges by Kyle Bass
Still, shedding light on patent missteps, especially given the high drug costs they enable, is a good thing. The efforts by Mr. Bass and Mr. Spangenberg to highlight problematic patents, whatever role they play in promoting their own investments, may also encourage others to make their own challenges.
The NYT post did not mention the challenges by Bass to patents related to multiple sclerosis [MS] drugs, including related to Ampyra and Tecfidera.
For example: https://www.pharmapatentsblog.com/2015/09/08/board-boots-bass-tecfidera-ipr-on-the-merits/